Meet the startups of the Innovation Challenge P3Dx

Within the Innovation Challenge P3Dx, the past period has been spent not only on the development of promising innovations, but also on making the participating startups and their stories more visible.

In collaboration with Ten Cate Productions, short videos have been produced for each of the participating startups. In these videos, the teams describe their technology, their ambition, and the contribution they are making — with support from the Innovation Challenge P3Dx — to innovation in diagnostics and pandemic preparedness.

With this video series, P3Dx wants to show how diverse and promising these innovations are. The videos help to bring the startups and their solutions to the attention of a broader group of stakeholders, and they illustrate how the challenge is contributing to the development of new diagnostic applications.

These are the five startups:

Nostics

Nostics is developing a lab-independent platform that can detect pathogens without relying on chemical reagents. The team is working on a method to rapidly assess the susceptibility of pathogens to medicines — an important step towards targeted treatment and better use of therapies.

Meet Nostics

Rapidemic

Rapidemic's technology brings the power of molecular diagnostics closer to the user — from the central laboratory to the general practitioner and potentially even to the home setting. The team is optimising its assay so that it performs better at room temperature and becomes more broadly deployable in a pandemic context.

Meet Rapidemic

QVQ

QVQ is building a highly diverse antibody library. The goal is to increase the likelihood that therapeutic or diagnostic antibodies can be made available more quickly when a new pandemic threat emerges.

Meet QVQ

CCassured

CCassured is developing a highly accurate molecular diagnostic solution based on CRISPR-Cas technology. The team is advancing this approach with the aim of enabling robust and scalable diagnostics at moments when fast and reliable testing is essential.

Meet CCAssured

Vysens

Vysens is developing a lab-independent platform to measure immune responses quickly. The team is working on the integration of simultaneous virus detection and automated data analysis. With this, the technology can contribute to better-informed — and potentially less far-reaching — measures during outbreaks.

Meet Vysens